argenx NV ADR (ARGX)vsOpus Genetics, Inc. (IRD)
ARGX
argenx NV ADR
$782.17
-0.65%
HEALTHCARE · Cap: $49.20B
IRD
Opus Genetics, Inc.
$4.99
-6.90%
HEALTHCARE · Cap: $356.30M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 33307% more annual revenue ($4.74B vs $14.20M). ARGX leads profitability with a 31.4% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 75/100 (B).
ARGX
Strong Buy75
out of 100
Grade: B
IRD
Avoid17
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.2%
Fair Value
$2329.77
Current Price
$782.17
$1547.60 discount
Intrinsic value data unavailable for IRD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Safe zone — low bankruptcy risk
Every $100 of equity generates 20 in profit
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 165.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : IRD
The strongest argument for IRD centers on Debt/Equity.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : IRD
The primary concerns for IRD are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ARGX profiles as a growth stock while IRD is a value play — different risk/reward profiles.
IRD carries more volatility with a beta of 0.63 — expect wider price swings.
ARGX is growing revenue faster at 62.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (75/100 vs 17/100), backed by strong 31.4% margins and 62.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Opus Genetics, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Opus Genetics, Inc. (IRD) is a leading biotechnology firm focused on developing innovative gene therapies for rare retinal diseases that threaten vision. Utilizing advanced research and proprietary gene-editing technologies, Opus aims to address critical unmet medical needs with transformative solutions designed to restore sight. The company's commitment to ocular health, coupled with its robust pipeline supported by ongoing clinical trials and strategic collaborations, positions Opus as a key player in the biotech sector. This innovative approach not only enhances patient outcomes but also presents significant value creation opportunities for investors interested in healthcare advancements.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?